Suchergebnisse - "Cook, Gordon"

PubPharm (5)

1

COVID-19 vaccination in patients with multiple myeloma : a consensus of the European Myeloma Network

enthalten in: The Lancet. Haematology | 2021

von Ludwig, H. | Sonneveld, P. | Facon, T. | +33

2

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Jackson, G. | Davies, F. | Pawlyn, C. | +20

3

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile) : a development and validation study

enthalten in: The Lancet. Haematology | 2019

von Cook, G. | Royle, K. | Pawlyn, C. | +10

4

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six) : a multicentre, open-label, phase 1/2 trial

enthalten in: The Lancet. Haematology | 2016

von Popat, R. | Brown, S. | Flanagan, L. | +10

CommentIn: Lancet Haematol. 2016 Dec;3(12):e552-e553. - PMID 27843121

5

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2016

von Cook, G. | Ashcroft, A. | Cairns, D. | +17

1
[1]